<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antibiotic therapy for treatment of osteomyelitis or prosthetic joint infection in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antibiotic therapy for treatment of osteomyelitis or prosthetic joint infection in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antibiotic therapy for treatment of osteomyelitis or prosthetic joint infection in adults</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Infectious agent</td> <td class="subtitle1">Antibiotic regimen</td> <td class="subtitle1">Dosing</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Empiric therapy</td> </tr> <tr class="divider_bottom"> <td class="indent1"> </td> <td>Vancomycin PLUS a third- or fourth-generation cephalosporin (such as ceftriaxone, ceftazidime, or cefepime)</td> <td>As summarized below</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Pathogen-specific therapy</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="5">Staphylococci, methicillin susceptible*</td> <td>Nafcillin</td> <td>2 g IV every 4 hours</td> </tr> <tr> <td>Oxacillin</td> <td>2 g IV every 4 hours</td> </tr> <tr> <td>Cefazolin</td> <td>2 g IV every 8 hours</td> </tr> <tr> <td>Flucloxacillin</td> <td>2 g IV every 6 hours</td> </tr> <tr class="divider_bottom"> <td>Ceftriaxone<sup>¶</sup></td> <td>2 g IV every 24 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="5">Staphylococci, methicillin resistant*</td> <td colspan="2"><strong>Regimen of choice:</strong></td> </tr> <tr> <td class="indent1">Vancomycin<sup>Δ</sup></td> <td> <p>Loading dose<sup>◊</sup>: 20 mg/kg</p> <p>Initial maintenance dose and interval determined by nomogram<sup>§</sup>: typically 15 to 20 mg/kg every 8 to 12 hours for most patients with normal renal function</p> Subsequent dose and interval adjustments based on AUC-guided or trough-guided serum concentration monitoring<sup>¥</sup></td> </tr> <tr> <td colspan="2"><strong>Alternative regimens:</strong><sup>‡</sup></td> </tr> <tr> <td class="indent1">Daptomycin<sup>†</sup></td> <td>6 to 10 mg/kg IV once daily</td> </tr> <tr class="divider_bottom"> <td class="indent1">Teicoplanin (where available)**<sup>,¶¶</sup></td> <td>12 mg/kg IV every 12 hours for 3 to 5 doses, followed by 12 mg/kg once daily</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="2">Staphylococci, adjunctive agents*</td> <td>Rifampin</td> <td>300 to 450 mg orally twice daily</td> </tr> <tr class="divider_bottom"> <td>Fusidic acid (where available)**</td> <td>500 mg orally 3 times daily</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="7">Gram-negative organisms</td> <td>Ciprofloxacin<sup>ΔΔ,</sup><sup>◊◊,</sup><sup>§§</sup></td> <td>750 mg orally twice daily or 400 mg IV every 12 hours; if treating Pseudomonas, increase IV dose to 400 mg IV every 8 hours</td> </tr> <tr> <td>Levofloxacin<sup>◊◊,</sup><sup>§§</sup></td> <td>750 mg orally or IV once daily</td> </tr> <tr> <td>Ceftriaxone<sup>¥¥</sup></td> <td>2 g IV every 24 hours</td> </tr> <tr> <td>Ceftazidime<sup>◊◊</sup></td> <td>2 g IV every 8 hours</td> </tr> <tr> <td>Cefepime<sup>◊◊</sup></td> <td>2 g IV every 8 to 12 hours</td> </tr> <tr> <td>Ertapenem<sup>¥¥</sup></td> <td>1 g IV every 24 hours</td> </tr> <tr class="divider_bottom"> <td>Meropenem<sup>◊◊</sup></td> <td>1 g IV every 8 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="10">Enterococci<sup>‡‡</sup></td> <td colspan="2"><strong>Monotherapy regimens:</strong></td> </tr> <tr> <td class="indent1">Ampicillin</td> <td>12 g IV every 24 hours, either continuously or in 6 equally divided doses</td> </tr> <tr> <td class="indent1">Aqueous crystalline penicillin G</td> <td>20 to 24 million units IV every 24 hours, either continuously or in 6 equally divided doses</td> </tr> <tr> <td class="indent1">Vancomycin<sup>Δ</sup></td> <td>20 mg/kg loading dose, then 15 mg/kg IV every 12 hours, not to exceed 2 g per dose</td> </tr> <tr> <td class="indent1">Daptomycin<sup>†</sup></td> <td>6 to 10 mg/kg IV once daily</td> </tr> <tr> <td class="indent1">Teicoplanin (where available)**<sup>,¶¶</sup></td> <td>12 mg/kg IV every 12 hours for 3 to 5 doses, followed by 12 mg/kg once daily</td> </tr> <tr> <td colspan="2"><strong>Combination therapy regimen:</strong></td> </tr> <tr> <td class="indent1">Ampicillin</td> <td>12 g IV every 24 hours, given either continuously or in 6 equally divided doses</td> </tr> <tr> <td class="indent2" colspan="2"><strong>PLUS</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1">Ceftriaxone</td> <td>2 g IV every 12 to 24 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="5">Streptococci, penicillin sensitive</td> <td colspan="2"><strong>One of the following:</strong></td> </tr> <tr> <td class="indent1">Aqueous crystalline penicillin G</td> <td>20 to 24 million units IV every 24 hours, either continuously or in 6 equally divided doses</td> </tr> <tr> <td class="indent1">Ampicillin</td> <td>12 g IV every 24 hours, either continuously or in 6 equally divided doses</td> </tr> <tr> <td class="indent1">Ceftriaxone</td> <td>2 g IV every 24 hours</td> </tr> <tr class="divider_bottom"> <td class="indent1">Vancomycin<sup>Δ</sup></td> <td>20 mg/kg loading dose, then 15 mg/kg/dose IV every 12 hours, not to exceed 2 g per dose, initially</td> </tr> <tr> <td class="indent1" rowspan="3"><em>Cutibacterium</em> (formerly <em>Propionibacterium</em>) <em>acnes<sup></sup></em><sup>††</sup></td> <td colspan="2"><strong>One of the following:</strong></td> </tr> <tr> <td class="indent1">Aqueous crystalline penicillin G</td> <td>20 million units IV every 24 hours, either continuously or in 6 divided doses</td> </tr> <tr> <td class="indent1">Ceftriaxone</td> <td>2 g IV every 24 hours</td> </tr> </tbody></table></div><div class="graphic_lgnd">In stable patients, antibiotics may be held pending establishment of microbiologic diagnosis or obtaining cultures from bone debridement or biopsy. The total duration of antibiotic therapy depends on individual patient circumstances (refer to the UpToDate content on treatment of osteomyelitis and prosthetic joint infection for further discussion). The doses in this table are intended for adults with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.</div><div class="graphic_footnotes">IV: intravenously; PJI: prosthetic joint infection; AUC: area under the 24-hour time-concentration curve.<br/>* For patients with staphylococcal PJI and residual hardware following surgery, we favor use of adjunctive rifampin. To mitigate the emergence of resistance, rifampin should not be started until the patient has received several days of anti-staphylococcal therapy. We favor administration of rifampin 450 orally twice daily; the dose may be reduced to 300 mg orally twice daily in the setting of nausea. There should be careful screening drug-drug interactions prior to initiation of rifampin.<br/>¶ Use of ceftriaxone for treatment of staphylococcal osteomyelitis is not universally accepted. In our practice, we use it as an alternative regimen for isolates with oxacillin minimum inhibitory concentration &lt;0.5 mcg/mL in the absence of concomitant bacteremia; once-daily dosing is a convenient outpatient regimen.<br/>Δ In adults, vancomycin is dosed based on actual body weight. Target troughs for vancomycin should be chosen with the guidance of a local infectious disease physician based on the pathogen, in vitro susceptibility, and the use of rifampin or local vancomycin therapy, with a target trough concentration of at least 10 mcg/mL. It is unknown if a higher vancomycin trough level of 15 to 20 mcg/mL is routinely needed. Refer to the UpToDate topic review on vancomycin parenteral dosing and serum concentration monitoring in adults.<br/><span class="lozenge">◊</span> Most patients with osteomyelitis or prosthetic joint infection due to methicillin-resistant <em>Staphylococcus aureus </em>(MRSA) are clinically stable; a loading dose of 20 mg/kg is adequate in such cases. For patients with critical illness and serious MRSA infection, a loading dose of up to 35 mg/kg may be warranted. The vancomycin loading dose is based on actual body weight, rounded to the nearest 250 mg increment and not exceeding 3000 mg.<br/>§ Refer to the UpToDate topic on vancomycin dosing for sample nomogram.<br/>¥ Refer to the UpToDate topic on vancomycin dosing for discussion of AUC-guided and trough-guided vancomycin dosing.<br/>‡ Ceftaroline has been used successfully for treatment of osteomyelitis but has been associated with increased risk of neutropenia. Pending further study, use of ceftaroline should be reserved for patients unable to receive other therapies. Ceftaroline susceptibility must be confirmed; the prevalence of resistance is high in some regions. Daptomycin may be used for vancomycin-resistant enterococci; confirm susceptibility.<br/>† Standard daptomycin dosing (as approved by the US Food and Drug Administration) for treatment of bacteremia or osteomyelitis is 6 mg/kg IV once daily. Because daptomycin exhibits concentration-dependent killing, some experts recommend doses of up to 8 to 10 mg/kg IV once daily, which appear safe; further study is needed.<br/>** Not available in the United States. Fusidic acid should not be used alone; it must be combined with a second active agent to reduce the likelihood of selection for drug resistance. When rifampin is combined with fusidic acid, fusidic levels may be reduced.<br/>¶¶ The teicoplanin dose should be adjusted to attain a trough concentration of &gt;20 mcg/mL.<br/>ΔΔ Oral ciprofloxacin at dose shown in table achieves therapeutic levels for treatment of <em>Pseudomonas aeruginosa</em>.<br/><span class="double_lozenge">◊◊</span> Ciprofloxacin, levofloxacin, ceftazidime, cefepime, and meropenem have activity against <em>P. aeruginosa</em>; confirm susceptibility.<br/>§§ The possibility of prolonged QTc interval, tendinopathy, neuropathy, or development of an aneurysm should be reviewed and monitored when using fluoroquinolones. For more information, please refer to the UpToDate topic on fluoroquinolones.<br/>¥¥ Ceftriaxone and ertapenem have no activity against <em>P. aeruginosa</em>, but are appropriate for other gram-negative organisms, if susceptible.<br/>‡‡ For treatment of infection due to penicillin-susceptible enterococci, it is unclear whether combination therapy is superior to monotherapy, particularly if thorough debridement is performed. In the setting of retained hardware, we favor combination therapy for PJI due to <em>Enterococcus faecalis </em>with ampicillin and ceftriaxone. We do not use this approach for treatment of PJI due to non<em>-faecalis </em>species of penicillin-susceptible enterococci because synergy with these agents in vitro is variable and clinical data are not available in patients with PJI due to non-<em>faecalis</em> species [11]. If antibiotic-impregnated material containing gentamicin is implanted at the time of debridement, then monotherapy is likely sufficient and we favor treatment with either intravenous ampicillin or penicillin (vancomycin or daptomycin are acceptable alternative agents for patients with proven beta-lactam hypersensitivity). For treatment of infection due to penicillin-resistant enterococci, the preferred agent is vancomycin; daptomycin or teicoplanin (where available) are acceptable alternative agents.<br/>†† For patients with <em>Cutibacterium</em> spp infection and beta-lactam hypersensitivity, reasonable alternative agents include vancomycin, a tetracycline (doxycycline or minocycline), or moxifloxacin.</div><div class="graphic_reference">Data from:

<ol>
<li>Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013; 56:e1.</li>
<li>Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis 2015; 61:e26.</li>
<li>Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177.</li>
<li>Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Ther Chemother 2006; 50:3245.</li>
<li>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:285.</li>
<li>Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus Aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.</li>
<li>Teicoplanin. The UK electronic Medicines Compendium (eMC) summary of product characteristics. Last updated February 01, 2018. UK electronic Medicines Compendium. (Available online at https://www.medicines.org.uk/emc/ (Accessed January 28, 2019)).</li>
<li>Sodium fusidate. The UK electronic Medicines Compendium (eMC) summary of product characteristics. Last updated August 30, 2018. UK electronic Medicines Compendium. (Available online at https://www.medicines.org.uk/emc/ (Accessed January 28, 2019)).</li>
<li>Euba G, Lora-Tamayo J, Murillo O, et al. Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis. Antimicrob Agents Chemother 2009; 53:4305.</li>
<li>Calhoun JH, Manring MM. Adult osteomyelitis. Infect Dis Clin North Am 2005; 19:765.</li>
<li>Pushkin R, Iglesias-Ussel MD, Keedy K, et al. A randomized study evaluating oral fusidic acid (CEM-102) in combination with oral rifampin compared with standard-of-care antibiotics for treatment of prosthetic joint infections: A newly identified drug-drug interaction. Clin Infect Dis 2016; 63:1599.</li>
<li>Lorenzo MP, Kidd JM, Jenkins SG, et al. In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium. J Antimicrob Chemother 2019; 74:2269.</li>
<li>Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus Aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.</li>
</ol></div><div id="graphicVersion">Graphic 121445 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
